Skip to main content

Table 3 Comparison of clinical and demographic characteristics of patients with positive cytomegalovirus antigenemia according to the outcome: survivor or death

From: Incidence of Cytomegalovirus Antigenemia in patients with autoimmune rheumatic diseases: a 3-year retrospective study

  Death
n = 10
Survivor
n = 11
p
Ageb (years) 44.3 ± 23.4 35.5 ± 18.3 0.32
Lymphocyte Count (/μL)b 447.2 ± 368.2 870.3 ± 692.9 0.06
CMV-Agb,c 113 ± 205,2 29 ± 52.9 0.67
Oral glucocorticosteroids (mg/ day)a,b 107 ± 55.4 71.7 ± 46.3 0.07
Methylprednisolone Pulse Therapy, n
 Yes 3 (30%) 8 (72.2%) 0.19
 No 7 (70%) 4 (36.6%)
Hospitalization timeb 24.3 ± 23.9 56.6 ± 35.1 0.017
Hospitalization time until CMV-Ag be requested (days)b 9.9 ± 14 12.9 ± 10.5 0.42
Time of symptoms until CMV-Ag be requested (days)b 7.9 ± 8.2 7.8 ± 6.4 0.77
Time from the first positive CMV-Ag to specific treatment be started (days) b 3.4 ± 2.6 3.3 ± 3.7 0.54
CMV suspicious cause, n
 Cytopenia 2 (20%) 4 (36.4%)  
 Cytopenia e GIT 0 (0) 1 (9.1%)  
 GIT 2 (20%) 3 (27.3%) 0.59
 Pneumonia 4 (40%) 4 (36.3%)  
 Cytopenia e Pneumonia 2 (20%) 0 (0)  
  1. CMV-Ag: cytomegalovirus antigenemia, b mean ± standard deviation, c cels / 200.000polimorphonuclear. aMaximum corticosteroid dose during hospitalization. GIT gastrointestinal tract. Cutoff value of 10 positive cores for CMV antigenemia